As part of a recently announced reorganization GlaxoSmithKline is planning to cut hundreds of jobs in the US and an announcement by Dierdre Connelly who heads North American operations is expected on Dec  according to Bloomberg News Some layoffs would not be surprising given that the drug maker noted in late October the reorganization would reduce expenses by about  billion over the next three years The reorganization come as Glaxo navigates a challenging stretch In the US which is its biggest market sales have been declining  they fell  in the third quarter this year  amid increasing competition for respiratory treatments Revenue generated by these  medicines  its biggest product category  fell  to roughly  billion thanks largely to slumping sales of Advair its bestselling treatment Advair sales dropped  to  billion reflecting in part price cuts brought about by tougher negotiations with insurers